Outcomes of Pregnancies from the Tildrakizumab Phase 1-3 Clinical Development Program.

Outcomes of Pregnancies from the Tildrakizumab Phase 1-3 Clinical Development Program. Br J Dermatol. 2020 Jan 29;: Authors: Haycraft K, DiRuggiero D, Rozzo SJ, Mendelsohn AM, Bhutani T Abstract Approximately 50% of patients with psoriasis are female, the majority of whom are of childbearing potential. Tildrakizumab, a high-affinity, humanised, immunoglobulin (Ig)G1κ, anti-interleukin (IL)-23p19 monoclonal antibody, demonstrated efficacy in treatment of moderate to severe chronic plaque psoriasis and was well tolerated in clinical studies. IgG antibodies are actively transported across the placental barrier via placental Fc receptors beginning at approximately gestational week 13. PMID: 31995637 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31995637?dopt=Abstract

Source: The British Journal of Dermatology - January 28, 2020 Category: Dermatology Authors: Haycraft K, DiRuggiero D, Rozzo SJ, Mendelsohn AM, Bhutani T Tags: Br J Dermatol Source Type: research